6547 Stock Overview
A biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 6547 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Medigen Vaccine Biologics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$37.15 |
| 52 Week High | NT$70.70 |
| 52 Week Low | NT$33.70 |
| Beta | 0.78 |
| 1 Month Change | -5.47% |
| 3 Month Change | -17.54% |
| 1 Year Change | -47.00% |
| 3 Year Change | -80.29% |
| 5 Year Change | 83.01% |
| Change since IPO | 74.88% |
Recent News & Updates
Shareholder Returns
| 6547 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 0.3% | 1.6% | 0.4% |
| 1Y | -47.0% | 2.1% | 27.0% |
Return vs Industry: 6547 underperformed the TW Biotechs industry which returned 2.6% over the past year.
Return vs Market: 6547 underperformed the TW Market which returned 27.5% over the past year.
Price Volatility
| 6547 volatility | |
|---|---|
| 6547 Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6547 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6547's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Leo Lee | www.medigenvac.com |
Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Zhubei, Taiwan.
Medigen Vaccine Biologics Corporation Fundamentals Summary
| 6547 fundamental statistics | |
|---|---|
| Market cap | NT$12.21b |
| Earnings (TTM) | -NT$640.49m |
| Revenue (TTM) | NT$648.17m |
18.8x
P/S Ratio-19.1x
P/E RatioIs 6547 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6547 income statement (TTM) | |
|---|---|
| Revenue | NT$648.17m |
| Cost of Revenue | NT$204.67m |
| Gross Profit | NT$443.50m |
| Other Expenses | NT$1.08b |
| Earnings | -NT$640.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.95 |
| Gross Margin | 68.42% |
| Net Profit Margin | -98.81% |
| Debt/Equity Ratio | 0.6% |
How did 6547 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 06:21 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medigen Vaccine Biologics Corporation is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hsuan Chen | KGI Securities Co. Ltd. |
| Yijun Chen | SinoPac Securities Investment Service |